{"id":"tacrolimus-arm-b","safety":{"commonSideEffects":[{"rate":"10-50","effect":"Nephrotoxicity"},{"rate":"10-30","effect":"Neurotoxicity (tremor, headache, paresthesia)"},{"rate":"20-50","effect":"Hypertension"},{"rate":"10-30","effect":"Hyperglycemia"},{"rate":"20-40","effect":"Infection"},{"rate":"10-20","effect":"Hyperkalemia"},{"rate":"5-15","effect":"Gastrointestinal disturbances"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus binds to the immunophilin FKBP12, and this complex inhibits calcineurin, a serine/threonine phosphatase essential for dephosphorylating NFAT. This prevents NFAT from entering the nucleus and activating genes required for T-cell cytokine production and proliferation. The result is potent immunosuppression, making it effective for preventing organ rejection and treating autoimmune conditions.","oneSentence":"Tacrolimus inhibits calcineurin phosphatase, blocking T-cell activation and proliferation by preventing nuclear translocation of NFAT transcription factors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:52.442Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prophylaxis (kidney, heart, liver, pancreas)"},{"name":"Atopic dermatitis"},{"name":"Autoimmune conditions (off-label use in various settings)"}]},"trialDetails":[{"nctId":"NCT01861106","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-24","conditions":"GATA2, Immunodeficiency, MDS","enrollment":144},{"nctId":"NCT06120140","phase":"PHASE2","title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-02-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":300},{"nctId":"NCT03970096","phase":"PHASE2","title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-11-19","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT06872333","phase":"PHASE2","title":"Allo HSCT for High Risk Hemoglobinopathies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-11-19","conditions":"Graft Failure, Sickle Cell Disease, Hemoglobinopathies","enrollment":62},{"nctId":"NCT06918990","phase":"PHASE2","title":"Treatment of Antibody-Mediated Rejection (ABMR) With CarBel","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-15","conditions":"Kidney Transplant Rejection","enrollment":25},{"nctId":"NCT06692426","phase":"PHASE1","title":"Trial of Cell Based Therapy for DMD","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2025-03-20","conditions":"Duchenne Muscular Dystrophy","enrollment":8},{"nctId":"NCT05027945","phase":"PHASE2","title":"A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-23","conditions":"Immunodeficiency, Hematopoietic Stem Cell Transplantation","enrollment":54},{"nctId":"NCT07349771","phase":"PHASE2","title":"Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-31","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":72},{"nctId":"NCT05457556","phase":"PHASE3","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-03-15","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":435},{"nctId":"NCT05088356","phase":"PHASE1","title":"Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-09-07","conditions":"Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia","enrollment":60},{"nctId":"NCT01743131","phase":"PHASE2","title":"Abatacept as GVHD Prophylaxis Phase 2","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2013-02-01","conditions":"Graft vs Host Disease, Malignancy","enrollment":186},{"nctId":"NCT05907746","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-11-29","conditions":"GATA2, Immunodeficiency","enrollment":7},{"nctId":"NCT05031897","phase":"PHASE2","title":"Two Step Haplo With Radiation Conditioning","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2021-10-25","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult T-Cell Leukemia/Lymphoma","enrollment":63},{"nctId":"NCT03320642","phase":"PHASE1","title":"GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2018-02-27","conditions":"Hematologic Malignancies","enrollment":84},{"nctId":"NCT03779854","phase":"PHASE2","title":"Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-08-29","conditions":"Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage","enrollment":68},{"nctId":"NCT04339777","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-22","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases","enrollment":66},{"nctId":"NCT07157514","phase":"PHASE2, PHASE3","title":"Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML","status":"NOT_YET_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2026-01","conditions":"Acute Leukemia, Myeloid Leukemia, Acute Myelogenous Leukemia","enrollment":306},{"nctId":"NCT07053462","phase":"PHASE1, PHASE2","title":"CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk","status":"RECRUITING","sponsor":"AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC","startDate":"2025-06-01","conditions":"End-Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Renal Disease With Renal Transplant","enrollment":90},{"nctId":"NCT06412497","phase":"PHASE2","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-06-05","conditions":"Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia","enrollment":60},{"nctId":"NCT02220985","phase":"PHASE2","title":"Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2015-02-03","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage","enrollment":84},{"nctId":"NCT02988466","phase":"PHASE2","title":"Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-01-24","conditions":"Hematologic Malignancies","enrollment":78},{"nctId":"NCT02766465","phase":"PHASE2","title":"Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-03-16","conditions":"Sickle Cell Disease","enrollment":138},{"nctId":"NCT05365672","phase":"PHASE2","title":"Clinical Trial With Donor Modified Immune Cells in Living Donor Kidney Transplantation","status":"RECRUITING","sponsor":"TolerogenixX GmbH","startDate":"2022-05-04","conditions":"Kidney Transplantation","enrollment":126},{"nctId":"NCT04561986","phase":"PHASE3","title":"TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2022-02-01","conditions":"Antibody-mediated Rejection","enrollment":50},{"nctId":"NCT02582775","phase":"PHASE2","title":"MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2016-03","conditions":"Epidermolysis Bullosa","enrollment":17},{"nctId":"NCT02498977","phase":"PHASE4","title":"Liver Immunosuppression Free Trial","status":"TERMINATED","sponsor":"King's College London","startDate":"2015-10","conditions":"Transplantation, Liver","enrollment":116},{"nctId":"NCT04048161","phase":"PHASE4","title":"Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric Patients With Nephrotic Syndrome","status":"COMPLETED","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2019-11-12","conditions":"Nephrotic Syndrome in Children","enrollment":270},{"nctId":"NCT04415476","phase":"PHASE2","title":"Standard Therapy Using Tacrolimus, Mycophenolate Mofetil and Prednisone For Chronic Lung Transplant Rejection (BOS)","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2020-06-30","conditions":"Disorder Related to Lung Transplantation, Chronic Rejection of Lung Transplant, Decreased Immunologic Activity","enrollment":""},{"nctId":"NCT02936505","phase":"NA","title":"Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2016-10-12","conditions":"Lung Transplantation, Allografts","enrollment":249},{"nctId":"NCT03266393","phase":"PHASE4","title":"Envarsus XR® in Adolescent Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2019-01-15","conditions":"Kidney Transplantation, Renal Transplantation, Grafting, Kidney","enrollment":28},{"nctId":"NCT04706559","phase":"NA","title":"Efficacy of Oral Supplementation of Probiotics in Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"B.P. Koirala Institute of Health Sciences","startDate":"2021-01-03","conditions":"Atopic Dermatitis","enrollment":98},{"nctId":"NCT01729494","phase":"PHASE4","title":"Belatacept Early Steroid Withdrawal Trial","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2012-09","conditions":"Renal Transplantation","enrollment":316},{"nctId":"NCT03066466","phase":"PHASE3","title":"Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT","status":"WITHDRAWN","sponsor":"Loyola University","startDate":"2019-12-10","conditions":"Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome","enrollment":""},{"nctId":"NCT01653847","phase":"NA","title":"Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2013-02","conditions":"End Stage Renal Failure With Renal Transplant","enrollment":88},{"nctId":"NCT02540395","phase":"NA","title":"Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"Prof. Dr. Petra Reinke","startDate":"2015-03","conditions":"Disorder Related to Renal Transplantation, Effects of Immunosuppressant Therapy","enrollment":184},{"nctId":"NCT02297126","phase":"NA","title":"A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-03","conditions":"Adverse Drug Reaction","enrollment":4465},{"nctId":"NCT04633733","phase":"PHASE1","title":"The Study of Pharmacokinetic Interactions Between HL237 and Tacrolimus","status":"UNKNOWN","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2020-08-22","conditions":"Healthy Male Volunteers","enrollment":24},{"nctId":"NCT00914940","phase":"PHASE2","title":"Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-12-17","conditions":"Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes","enrollment":41},{"nctId":"NCT00629122","phase":"PHASE4","title":"Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney Transplantation","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2008-02","conditions":"Kidney Failure, Chronic","enrollment":5},{"nctId":"NCT00520130","phase":"PHASE1, PHASE2","title":"Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-10-30","conditions":"Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease","enrollment":92},{"nctId":"NCT02115113","phase":"PHASE3","title":"REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-03-28","conditions":"Liver Transplantation","enrollment":78},{"nctId":"NCT00281879","phase":"PHASE2","title":"Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-02","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":200},{"nctId":"NCT01754389","phase":"PHASE2","title":"Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-01","conditions":"Graft Versus Host Disease","enrollment":138},{"nctId":"NCT00448201","phase":"PHASE2","title":"Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2011-01-07","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":71},{"nctId":"NCT01749111","phase":"PHASE3","title":"Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis","status":"TERMINATED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2012-12","conditions":"Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Myeloproliferative Disease","enrollment":3},{"nctId":"NCT00670410","phase":"PHASE1","title":"Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma","status":"TERMINATED","sponsor":"Columbia University","startDate":"2003-11","conditions":"Neuroblastoma","enrollment":15},{"nctId":"NCT00707759","phase":"PHASE3","title":"Steroid Withdrawal in Pediatric Renal Transplant: Impact on Growth, Bone Metabolism and Acute Rejection","status":"COMPLETED","sponsor":"Fondo Nacional de Desarrollo Científico y Tecnológico, Chile","startDate":"2008-06","conditions":"Kidney Diseases","enrollment":28},{"nctId":"NCT00322101","phase":"PHASE3","title":"Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2006-01","conditions":"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Adult Acute Myeloid Leukemia in Remission","enrollment":25},{"nctId":"NCT00724022","phase":"PHASE4","title":"Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation","status":"COMPLETED","sponsor":"University Hospital Freiburg","startDate":"2008-06","conditions":"Disorder Related to Renal Transplantation","enrollment":600},{"nctId":"NCT00004145","phase":"PHASE2","title":"Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"1998-11","conditions":"Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm","enrollment":16},{"nctId":"NCT00830297","phase":"PHASE2","title":"Treat-to-target Trial of Basal Insulin in Post-transplant Hyperglycemia","status":"COMPLETED","sponsor":"Marcus Saemann","startDate":"2009-01","conditions":"Hyperglycemia","enrollment":50},{"nctId":"NCT00223041","phase":"PHASE2, PHASE3","title":"Cranoc Lipid Study in Renal Transplantation","status":"TERMINATED","sponsor":"University Hospital Schleswig-Holstein","startDate":"2003-04","conditions":"Renal Transplantation","enrollment":200},{"nctId":"NCT00538265","phase":"PHASE4","title":"Benefit of Immunoprophylaxis on Fibrosis to Reduce Viral Load After Liver Transplantation","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2005-05","conditions":"Liver Transplantation","enrollment":100},{"nctId":"NCT01268995","phase":"PHASE2","title":"Improving Secretion of Insulin in New Onset Diabetes After Renal Transplantation","status":"TERMINATED","sponsor":"Medical University of Vienna","startDate":"2009-09","conditions":"New Onset Diabetes Mellitus After Renal Transplantation","enrollment":32},{"nctId":"NCT00644761","phase":"PHASE2","title":"PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2004-02","conditions":"Hepatitis B","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prograf"],"phase":"marketed","status":"active","brandName":"Tacrolimus (Arm B)","genericName":"Tacrolimus (Arm B)","companyName":"Weill Medical College of Cornell University","companyId":"weill-medical-college-of-cornell-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tacrolimus inhibits calcineurin phosphatase, blocking T-cell activation and proliferation by preventing nuclear translocation of NFAT transcription factors. Used for Organ transplant rejection prophylaxis (kidney, heart, liver, pancreas), Atopic dermatitis, Autoimmune conditions (off-label use in various settings).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}